STOCK TITAN

Aptevo Therapeutics Inc reported a $26.0M net loss for fiscal 2025. See the full APVO financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

Early RAINIER data for mipletamig in TP53‑mutated frontline AML show high remission and clinical benefit rates versus historical venetoclax plus azacitidine outcomes.

(Neutral)
Tags

Aptevo Therapeutics (APVO) reported a 93% clinical benefit rate for its mipletamig triplet regimen in evaluable frontline TP53‑mutated acute myeloid leukemia (AML) patients. Of 14 patients treated with mipletamig plus venetoclax and azacitidine, 13 derived clinical benefit and 11 (79%) achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi).

The 79% CR/CRi rate compares with a published 41% composite remission rate for venetoclax plus azacitidine alone in treatment‑naïve TP53‑mutated AML with poor‑risk cytogenetics. The ongoing RAINIER Phase 1b/2 trial is in dose optimization and is expected to complete this phase by year‑end, with regulatory interaction planned in 1H27. Mipletamig, Aptevo’s lead wholly owned bispecific candidate, has orphan drug designation for AML and is designed to target CD123‑expressing leukemic cells while aiming to limit cytokine release syndrome.

Loading...
Loading translation...

Positive

  • 93% clinical benefit rate (13 of 14 evaluable TP53‑mutated AML patients) with mipletamig plus venetoclax and azacitidine.
  • 79% CR/CRi rate (11 of 14 patients), including nine complete remissions, in this difficult‑to‑treat AML population.
  • Remission rate benchmark of 79% CR/CRi compares favorably with a published 41% composite remission rate for venetoclax plus azacitidine alone.
  • RAINIER dose‑optimization phase is ongoing with completion expected by year‑end, moving the program toward Phase 2 and regulatory discussions.
  • Mipletamig orphan drug designation for AML provides potential regulatory and market exclusivity advantages if successfully developed.

Negative

  • Small patient sample of 14 evaluable TP53‑mutated AML patients limits generalizability of current efficacy signals.
  • Early‑stage development: RAINIER is still in Phase 1b dose optimization, with key regulatory interaction not planned until 1H27, implying a long path to potential approval.

Market reaction after Phase 1b/2 clinical data: APVO -15.00%

-15.00% $2.21 372.1x vol
15m delay
-15.00% Vs previous close
-15.0% Trough in 2 min
$2.21 Last Price
$1.91 $2.69 Day Range
$4.00M Market Cap
372.1x Rel. Volume

Following this news, APVO has declined 15.00%, reflecting a significant negative market reaction. Argus tracked a trough of -15.0% from its starting point during tracking. Our momentum scanner has triggered 21 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $2.21. Trading volume is exceptionally heavy at 372.1x the average, suggesting significant selling pressure.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

The stock is dropping -10.8% following this news. The -15.38% reaction on August 12 followed financi...
Analysis

The stock is dropping -10.8% following this news. The -15.38% reaction on August 12 followed financing news, documenting market sensitivity around warrant issuance and potential share supply. The current clinical update still carried development-stage and funding risks.

Key Figures

Clinical Benefit Rate: 93% Evaluable Patients: 14 patients Patients With Clinical Benefit: 13 patients +5 more
8 metrics
Clinical Benefit Rate 93% Mipletamig triplet in evaluable frontline TP53-mutated AML patients
Evaluable Patients 14 patients TP53-mutated patients treated with mipletamig, venetoclax, and azacitidine
Patients With Clinical Benefit 13 patients Among 14 evaluable TP53-mutated patients
CR/CRi Rate 79% Mipletamig triplet results in evaluable TP53-mutated AML
CR/CRi Patients 11 patients Among 14 evaluable TP53-mutated patients
Complete Remissions 9 patients Among patients treated with the mipletamig triplet
Published Composite Remission Rate 41% Venetoclax plus azacitidine in treatment-naive TP53-mutated AML
Trial Phase Phase 1b/2 RAINIER dose optimization study

Historical Context

5 past events · Latest: Aug 14 (Neutral)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Aug 14 earnings report Neutral -13.5% Business update highlighted clinical progress, funding, collaboration, cash, and quarterly financing activity.
Aug 13 private financing Negative -13.5% Warrant exercise and PIPE generated proceeds while adding warrants and potential resale shares.
Aug 12 private financing Negative -15.4% Warrant inducement and PIPE financing added potential shares and warrants for working capital.
Jul 27 patent filing Positive -4.1% Patent application covered a Nectin-4 and PD-L1 dual-targeting backbone for solid tumors.
Jun 30 research grant Positive -2.4% Non-dilutive grant funded APVO451 IND-enabling work and candidate selection activities.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

APVO's recent news events were more often followed by negative 24-hour reactions, including after positive clinical, patent, and grant updates.

Key Terms

morphologic leukemia-free state, cytokine release syndrome, orphan drug designation, ind-enabling studies
4 terms
morphologic leukemia-free state medical
"Clinical benefit includes complete remission (CR), CRi, partial response (PR) and morphologic leukemia-free state"
Morphologic leukemia-free state (MLFS) is a clinical response in leukemia where doctors see no visible cancer cells in the bone marrow or blood under the microscope, although normal blood counts may not yet have recovered. For investors, MLFS is important because it signals that a therapy can clear detectable disease — like trimming visible weeds from a garden while roots remain — and is often used as an early measure of a drug’s activity, affecting trial outcomes, regulatory decisions, and commercial prospects.
cytokine release syndrome medical
"reduce the likelihood and severity of cytokine release syndrome"
An intense immune overreaction in which the body's defense system releases a large surge of signaling proteins, causing fever, low blood pressure, breathing trouble or organ stress; imagine the immune system's alarm going into overdrive and flooding the body with emergency responders. Investors care because this side effect can slow or block regulatory approval, increase clinical trial costs and liabilities, limit how widely a therapy can be used, and therefore affect a drug's market value and sales potential.
orphan drug designation regulatory
"Mipletamig has received orphan drug designation for AML"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
ind-enabling studies regulatory
"Both preclinical molecules are expected to advance into investigational new drug (IND)-enabling studies"
Ind-enabling studies are early research efforts that test whether a new drug or treatment is safe and effective enough to move forward in development. They are like preliminary tests to ensure a product works as intended before investing more resources into large-scale trials. For investors, these studies are important because successful results can signal potential progress toward bringing a new product to market, impacting its future value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success

SEATTLE, WA / ACCESS Newswire / September 3, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced a 93% clinical benefit rate with its mipletamig triplet in evaluable frontline acute myeloid leukemia (AML) patients with TP53 mutations, one of the most difficult-to-treat forms of the disease and a patient population that has historically responded poorly to treatment.

"TP53-mutated AML remains one of the most challenging AML subpopulations to treat," said Dirk Huebner, M.D., Chief Medical Officer of Aptevo. "Seeing this level of clinical benefit with the mipletamig triplet in a patient population that historically has not responded well to treatment is exciting. These results support mipletamig as a promising frontline treatment for one of the most difficult-to-treat forms of AML."

Of 14 evaluable TP53-mutated patients treated with mipletamig in combination with venetoclax and azacitidine, including two patients from the previously completed dose expansion trial, 13 (93%) experienced clinical benefit.* Eleven patients achieved CR or CRi (79%), including nine complete remissions.

*Clinical benefit includes complete remission (CR), complete remission with incomplete hematologic recovery (CRi), partial response (PR) and morphologic leukemia-free state (MLFS).

These results are encouraging because patients with TP53-mutated AML have historically had limited treatment success. The 79% CR/CRi rate observed with the mipletamig triplet compares favorably with a published 41% composite remission rate** for venetoclax plus azacitidine in treatment-naïve patients with poor-risk cytogenetics and TP53-mutated AML.

**Benchmark comparison based on Pollyea DA, et al. Clinical Cancer Research. 2022;28(24):5272-5279. Comparison is to treatment-naïve patients with poor-risk cytogenetics and TP53-mutated AML treated with venetoclax plus azacitidine.

TP53-mutated AML is one of the most difficult forms of acute myeloid leukemia to treat, with patients historically experiencing lower remission rates and poorer outcomes than those with other forms of AML. Because TP53 mutations can make leukemia cells more resistant to treatment, achieving deep and durable responses in this patient population has been particularly challenging. As a result, the robust responses observed with mipletamig in TP53-mutated AML are especially encouraging and highlight its potential to address a significant unmet medical need.

Currently, the RAINIER study is evaluating mipletamig in combination with venetoclax and azacitidine in frontline AML patients who are unfit to receive standard high-intensity chemotherapy in a dose optimization trial. This phase of the trial is expected to be completed by year-end, and regulatory interaction is planned for 1H27 to determine next steps.

About the RAINIER Trial
RAINIER, a frontline AML study, is a Phase 1b/2 dose optimization, multi-center, multi-cohort, open-label study. Subjects are adults aged 18 or older, newly diagnosed with AML who are not eligible for intensive induction chemotherapy. RAINIER will be conducted in two parts. First, a Phase 1b dose optimization study in frontline AML patients followed by a Phase 2 study. The Phase 1b trial consists of 28-day cycles of treatment across multiple, sequential cohorts.

About Mipletamig
Aptevo's wholly owned lead proprietary drug candidate, mipletamig, is being evaluated for the treatment of AML. Mipletamig is designed to redirect the patient's immune system to destroy leukemic cells and leukemic stem cells expressing CD123, which is overexpressed on leukemic stem cells and AML blasts. Mipletamig is designed to engage both leukemic cells and T cells of the immune system and bring them closely together to trigger the destruction of leukemic cells. Mipletamig is purposefully designed to reduce the likelihood and severity of cytokine release syndrome by using the CRIS-7-derived CD3 binding pathway, an approach that differentiates Aptevo from competitors.

About Aptevo
Aptevo Therapeutics Inc. (Nasdaq: APVO) is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for the treatment of cancer. The Company's lead clinical candidate, mipletamig, is currently being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML under the Orphan Drug Act.

In the solid tumor space, Aptevo's lead assets are focused on well-established targets to progress novel immunomodulatory platform backbones that are conditionally active only in the tumor.

This work includes advancing APVO451, a targeted trispecific immunotherapy candidate for solid tumors, and a strategic collaboration with Niowave to develop up to three radiopharmaceutical oncology programs. The first radiopharmaceutical program is expected to target nectin-4, a tumor-associated antigen expressed in multiple solid tumor types. Both preclinical molecules are expected to advance into investigational new drug (IND)-enabling studies in 2027.

The Company's eight pipeline candidates are created using its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms, which are designed to generate differentiated multispecific therapeutics. The Aptevo mission is to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit www.aptevotherapeutics.com.

Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, statements regarding Aptevo's expectations about the activity, efficacy, safety, tolerability and durability of mipletamig, including in combination with venetoclax and azacitidine; statements related to the progress of the RAINIER trial, including statements related to anticipated clinical and regulatory milestones; statements related to the responses observed in patients with TP53-mutated AML and whether further study of mipletamig in combination with venetoclax + azacitidine will continue to show clinical benefit in patients with TP53-mutated AML; whether Aptevo's strategy will translate into an improved overall survival rate in acute myeloid leukemia (AML); whether the mipletamig data in combination therapy will be indicative of later stage clinical trials; whether Aptevo's strategy will translate into improved overall survival in AML, especially among patient subgroups with poor prognosis; its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platform; development and continued development of Aptevo's current and potential future molecules, including Aptevo's trispecific candidates and their future development and efficacy with respect to addressing multiple solid tumor types; whether pre-clinical studies of Aptevo's trispecific candidates will show the desired anti-tumor efficacy, mechanism of action and safety profile and whether Aptevo's trispecific candidates will function with new mechanisms of action compared to our previous candidates and synergistically induce a biological response; the potential benefits, timing, scope and outcomes of the co-development collaboration with Niowave; and any statements containing the words "may," "continue to," "believes," "expects," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements.

These forward-looking statements are based on Aptevo's current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors are cautioned not to place undue reliance on any forward-looking statement. There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems; adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, and its subsequent reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events or circumstances.

CONTACT:
Miriam Weber Miller
Vice President, Investor Relations & Corporate Communications
Aptevo Therapeutics
Email: IR@apvo.com or Millerm@apvo.com
Phone: 206-859-6628

SOURCE: Aptevo Therapeutics



View the original press release on ACCESS Newswire

FAQ

What clinical results did Aptevo (APVO) report for mipletamig in TP53‑mutated frontline AML?

Aptevo reported a 93% clinical benefit rate for mipletamig combined with venetoclax and azacitidine in 14 evaluable frontline TP53‑mutated AML patients. Thirteen patients experienced clinical benefit and 11 (79%) achieved complete remission or complete remission with incomplete hematologic recovery.

How does mipletamig’s remission rate compare with venetoclax plus azacitidine alone in TP53‑mutated AML for APVO?

In this early study, mipletamig plus venetoclax and azacitidine produced a 79% CR/CRi rate, compared with a published 41% composite remission rate for venetoclax plus azacitidine alone in treatment‑naïve TP53‑mutated AML patients with poor‑risk cytogenetics.

How many TP53‑mutated AML patients were treated with the mipletamig triplet regimen in the Aptevo (APVO) study?

Fourteen evaluable TP53‑mutated frontline AML patients received mipletamig in combination with venetoclax and azacitidine, including two patients from a previously completed dose expansion trial. Of these, 13 showed clinical benefit and 11 achieved CR or CRi.

What is the RAINIER trial investigating for Aptevo (APVO) and when is the current phase expected to complete?

The RAINIER trial is a Phase 1b/2, multi‑center, open‑label study evaluating mipletamig plus venetoclax and azacitidine in newly diagnosed AML patients unfit for intensive chemotherapy. The dose‑optimization Phase 1b portion is expected to be completed by year‑end, with further development decisions to follow.

When does Aptevo (APVO) plan regulatory interaction for mipletamig in AML after the RAINIER trial?

Regulatory interaction for mipletamig in AML is planned for the first half of 2027 (1H27), after completion of the current dose‑optimization phase of the RAINIER trial, to determine potential next steps in the development program.

What is mipletamig and how is it designed to work in AML for Aptevo (APVO)?

Mipletamig is Aptevo’s wholly owned lead drug candidate for AML, designed to redirect the immune system to destroy CD123‑expressing leukemic cells and leukemic stem cells. It engages both leukemic cells and T cells and is purposefully designed to reduce cytokine release syndrome risk via a CRIS‑7‑derived CD3 binding pathway.

What other oncology programs does Aptevo (APVO) highlight alongside mipletamig in this announcement?

Aptevo highlights APVO451, a trispecific immunotherapy candidate for solid tumors, and a collaboration with Niowave to develop up to three radiopharmaceutical oncology programs, including a first program targeting nectin‑4. These preclinical molecules are expected to move into IND‑enabling studies in 2027.